SCHEMBL1474620

SCHEMBL1474620

CCc1cccc2oc(C(=O)O)c(O)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.47
GABRB2 P47870 1/20 0.47
EDNRA P25101 2/20 0.45
MCL1 Q07820 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
TTR P02766 4/20 0.40
GPR35 Q9HC97 1/20 0.38
KDM4E B2RXH2 3/20 0.37
AHR P35869 1/20 0.37
HSD17B10 Q99714 2/20 0.37
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
CLCN2 P51788 1/20 0.36
ELANE P08246 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607819 0.83 EDNRA (0.60) EDNRAMCL1NPC1RAB9AMAPT
SCHEMBL585271 0.82 EDNRA (0.44) GABRA1GABRB2EDNRAMCL1NPC1
SCHEMBL11194764 0.81 EDNRA (0.43) GABRA1GABRB2EDNRAMCL1NPC1
SCHEMBL28493571 0.80 ALDH1A1 (0.45) GABRA1GABRB2MAPTTTRKDM4E
SCHEMBL28509698 0.80 EDNRA (0.52) EDNRAMCL1NPC1RAB9AMAPT
SCHEMBL1474617 0.75 MAPT (0.52) EDNRAMCL1NPC1RAB9AMAPT
SCHEMBL17786596 0.74 KDM4E (0.46) EDNRAMCL1NPC1RAB9AKDM4E
SCHEMBL10743811 0.73 EDNRA (0.49) GABRA1GABRB2EDNRAMCL1NPC1
SCHEMBL27593837 0.72 EDNRA (0.59) EDNRAMCL1NPC1RAB9AMAPT
SCHEMBL27631295 0.72 CYP3A4 (0.68) MAPTKDM4EHSD17B10MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013083991-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY IMPERIAL INNOVATIONS LIMITED (GB) 2013-06-13 WO disclosed
US-7915300-B2 Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one MEDIVIR AB (SE) 2011-03-29 US disclosed
US-20080234260-A1 Cysteine Protease inhibitors MEDIVIR AB (SE) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234260-A1 Cysteine Protease inhibitors CTSS, CTSZ, CTSK GABRA1 3773/4885GABRB2 4094/4885EDNRA 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.